Thus, strategies to increase tumor penetration by CD8+ T cells via targeting mechanisms that restrict their intratumoral trafficking and accumulation would likely favor anti-tumor immunity and bolster the efficacy of current ICB therapies. The gene discussed is CD8A; the disease is neoplasm.